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Abstract
Background: Use of FDG-PET/CT for staging and restaging of lymphoma patients is widely incorporated into
current practice guidelines. Our aim was to prospectively evaluate the diagnostic performance of FDG-PET/MRI
and WB-DW-MRI compared with FDG-FDG-PET/CT using a tri-modality PET/CT-MRI system.
Methods: From 04/12 to 01/14, a total of 82 FDG-PET/CT examinations including an additional scientific MRI on a
tri-modality setup were performed in 61 patients. FDG-PET/CT, FDG-PET/MRI, and WB-DW-MRI were independently
analyzed. A lesion with a mean ADC below a threshold of 1.2 × 10−3 mm2/s was defined as positive for restricted
diffusion. FDG-PET/CT and FDG-PET/MRI were evaluated for the detection of lesions corresponding to lymphoma
manifestations according to the German Hodgkin Study Group. Imaging findings were validated by biopsy (n = 21),
by follow-up imaging comprising CT, FDG-PET/CT, and/or FDG-PET/MRI (n = 32), or clinically (n = 25) (mean follow-
up: 9.1 months).
Results: FDG-PET/MRI and FDG-PET/CT accurately detected 188 lesions in 27 patients. Another 54 examinations in
35 patients were negative. WB-DW-MRI detected 524 lesions, of which 125 (66.5 % of the aforementioned 188 lesions)
were true positive. Among the 188 lesions positive for lymphoma, FDG-PET/MRI detected all 170 instances of nodal
disease and also all 18 extranodal lymphoma manifestations; by comparison, WB-DW-MRI characterized 115 (67.6 %)
and 10 (55.6 %) lesions as positive for nodal and extranodal disease, respectively. FDG-PET/MRI was superior
to WB-DW-MRI in detecting lymphoma manifestations in patients included for staging (113 vs. 73), for restaging (75 vs.
52), for evaluation of high- (127 vs. 81) and low-grade lymphomas (61 vs. 46), and for definition of Ann Arbor stage
(WB-DW-MRI resulted in upstaging in 60 cases, including 45 patients free of disease, and downstaging in 4).
Conclusion: Our results indicate that FDG-PET/CT and FDG-PET/MRI probably have a similar performance in
the clinical work-up of lymphomas. The performance of WB-DW-MRI was generally inferior to that of both
FDG-PET-based methods but the technique might be used in specific scenarios, e.g., in low-grade lymphomas
and during surveillance.
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Background
Use of fluorodeoxyglucose positron emission tomog-
raphy/computed tomography (FDG-PET/CT) for staging
and restaging of lymphoma patients is now clinical rou-
tine and is widely incorporated into current practice
guidelines [1]. Recent advances in magnetic resonance
imaging (MRI) technology and MRI sequences have led
to the introduction of whole-body diffusion-weighted
MRI (WB-DW-MRI) and allowed for calculation of ap-
parent diffusion coefficients (ADC) [2]. WB-DW-MRI is
expected to improve staging accuracy due to the poten-
tial improvement in lesion-to-background contrast [3].
Previously published studies comparing WB-DW-MRI
and FDG-PET/CT reported kappa values for method
agreement ranging from 0.51 to 0.85 [4, 5]. The fact
that all major vendors offer hybrid scanners combining
MRI, PET, and/or CT technology allows for direct com-
parison of single imaging modalities as well as hybrid
approaches [6].
Potential advantages of WB-DW-MRI in comparison
with either FDG-PET/CT or FDG-PET/MRI include no ra-
diation burden, the possibility of protocol standardization,
and high tumor-to-background contrast; in addition, image
acquisition times are comparable.
Promising initial results encouraged authors to advocate
WB-DW-MRI as a potential replacement for FDG-PET/
CT [7]. However, as yet no prospectively validated ADC
criteria have been established for differentiation of lym-
phomatous from non-lymphomatous lymph nodes when
using WB-DW-MRI. Moreover, few data are currently
available regarding the performance of FDG-PET/MRI
and WB-DW-MRI as compared with FDG-PET/CT in
lymphoma patients.
The aim of this study was therefore to prospectively
evaluate the evaluate the diagnostic performance of
FDG-PET/MRI and WB-DW-MRI compared with FDG-
FDG-PET/CT using a tri-modality PET/CT-MRI system
that allows for a one-stop examination in a realistic
everyday clinical setting including pretreatment staging,
interim and end of treatment restaging, and surveillance.
Methods
Patient population
From April 2012 through January 2014, all patients re-
ferred for a clinical FDG-PET/CT examination for either
staging or restaging lymphoma were offered an additional
scientific MRI within a tri-m
odality setup. A total of 82 examinations were performed
in 61 patients, with 15 patients undergoing more than one
scan (ten patients, two examinations; four patients, three
examinations; and one patient, four examinations). No
further patient inclusion criteria were applied. Exclu-
sion criteria were unwillingness to participate in the
study, claustrophobia, MRI-incompatible medical
devices (e.g., cardiac pacemakers, neurostimulators,
cochlear implants, and insulin pumps), or possible pres-
ence of metallic fragments in the body. This prospective
study was approved by the ethics committee of the Can-
ton of Zurich and signed informed consent was obtained
from all patients prior to the examinations.
FDG-PET/CT and MRI
Sequential FDG-PET/CT and MRI were performed on a
tri-modality PET/CT-MRI setup (full ring, time-of-flight
Discovery PET/CT 690, 3 T Discovery MR 750w, both GE
Healthcare, Waukesha, WI, USA). The dedicated MRI-
and CT-compatible shuttle transfer mechanism connect-
ing the MRI and PET/CT systems allowed for PET/CT
scanning free of radiofrequency (RF) coil-induced artifacts
and ascertained the placement of dedicated RF coils for
MRI without repositioning of the patient [8, 9].
Patients fasted for at least 4 h prior to injection of a
standard FDG dose of 4.5 MBq per kg body weight [10].
After an uptake time of 30 min the patient was posi-
tioned on the shuttle table in the MRI suite and MRI
acquisition covering the region from the head to the
upper thighs was started. The images were acquired by
use of a GEM whole-body suite (GE Healthcare, Waukesha,
WI, USA). The MRI protocol included a T1-weighted
three-dimensional spoiled gradient echo pulse sequence
(LAVA) and diffusion-weighted images obtained in the
axial plane, both divided into four stations, with a total
MRI scan duration of 15–20 min (see Table 1 for scan-
ning parameters).
After completion of the MRI, coils were removed and
the patients were transferred to the PET/CT, still posi-
tioned on the shuttle board. In this way, it was ensured
that positioning of the patient within the PET/CT and
the MRI scanners was exactly the same.
Table 1 MRI scanning parameters
Parameter T1w LAVA DWI EPI-STIR
Repetition time/echo time (ms) 4.3/1.3 4175/100
Echo train length NA NA
Flip angle (°) 12 NA
Inversion time (ms) NA 200
Parallel imaging acceleration factor 2 2
Receiver bandwidth (kHz) 142.86 250
Field of view (cm) 50 44
Matrix 288 × 224 64 × 128
b value (s/mm) NA 0, 50, 500
NEX 1 NA
Number of directions NA 3
Abbreviations: T1w LAVA T1-weighted spoiled gradient echo pulse sequence,
DWI diffusion-weighted imaging sequence, EPI-STIR echo planar imaging-short
time inversion recovery, NEX number of excitations, NA not applicable
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After shuttle transfer to the adjacent PET/CT system
(after an overall uptake time of 60 min), unenhanced
low-dose CT and PET emission data were acquired from
the mid-thigh to the vertex of the skull. The low-dose
CT was acquired during shallow breathing in the head,
upper thorax, and pelvis areas and with non-forced expir-
ation breath hold in the diaphragm and upper abdomen.
Tube voltage was 120 kV (peak), reference tube current
12.35 mA/slice, automated dose modulation range 15–80
mAs/slice, collimation 64 × 0.625 mm, pitch 0.984:1, rota-
tion time 0.5 s, field of view (FOV) 50 cm, and noise index
20 %. CT image sets were reconstructed using an iterative
algorithm [Adaptive Statistical Iterative Reconstruction
(ASIR), GE Healthcare].
The PET data were acquired in 3-D time of flight
(TOF) mode with a scan duration of 2 min per bed pos-
ition, a 23 % overlap of bed positions, an axial FOV of
153 mm, and a 700-mm-diameter FOV. The emission
data were corrected for attenuation by use of the low-
dose CT and iteratively reconstructed [matrix size 256 ×
256, VUE Point FX (3D TOF-OSEM) with 3 iterations,
18 subsets]. Images were filtered in image space using
an in-plane Gaussian convolution kernel with a full-
width at half-maximum (FWHM) of 4.0 mm, followed
by a standard axial filter with a three-slice kernel. This
procedure has been used in this standard way in other
studies as well [11].
Image processing
The acquired FDG-PET/CT and MRI images were trans-
mitted to a dedicated review workstation (Advantage
Workstation, Version 4.5, GE Healthcare, Milwaukee,
WI, USA) that enables review of the PET, CT, and MRI
images side by side or in fused/overlay mode (FDG-
PET/CT; FDG-PET/MRI). Due to use of the calibrated
three-modality system, no software-based image registra-
tion was necessary. A previously conducted study vali-
dated the accuracy of image registration, with less than
4 mm lateral misalignment between CT, PET, and MRI
data sets, which is similar to the intrinsic error assessed
with phantom measurements [12].
Image analysis
Analysis was performed by a board-certified nuclear
medicine physician and a board-certified radiologist
with substantial experience in FDG-PET/CT. All im-
ages were evaluated for the presence of lymphoma
manifestations according to the German Hodgkin
Study Group (GHSG) protocol guidelines, including a
total of 34 possible anatomic sites divided into nodal
or organ involvement [3, 13–15].
Nodal involvement was considered to comprise
lymphoma manifestation at any of the following sites:
Waldeyer’s ring, upper cervical, cervical, supraclavicular,
infraclavicular, axillary, lung hilum, iliac and inguinal
(right or left), upper mediastinum, lower mediastinum,
liver hilum, spleen, splenic hilum, celiac, mesenteric, and
para-aortic. Organ involvement was characterized as
presence of a positive lesion for lymphoma in the lung
(right or left), liver, pleura, skeleton, pericardium, bone
marrow, or any other organ not previously described.
With regard to WB-DW-MRI, a positive lymphoma
manifestation was represented by a high-signal lesion on
high b-value WB-DW-MRI and a low signal on the corre-
sponding ADC map, using a mean ADC of 1.2 × 10−3
mm2/s as the threshold.
For assessment of lymphoma manifestation on FDG-
PET/CT and FDG-PET/MRI, a combination of morpho-
logic and functional findings was used. The morphologic
criteria for lymphoma manifestation were presence of a
mass-like lesion, presence of enlarged lymph nodes
greater than 1.0 cm in the short axis (and 1.5 cm for an-
gular lymph nodes), cluster formation, irregular bound-
ary of the lymph node capsule, and extracapsular lymph
node spread. The functional criterion was defined as
presence of an FDG-positive lesion with higher focal
FDG uptake than liver activity (Deauville criteria, see
below). For FDG-negative lesions, the morphologic cri-
teria were used.
Image validation and follow-up
Imaging findings were validated by biopsy (n = 21), by
follow-up imaging comprising CT, FDG-PET/CT, and/or
FDG-PET/MRI (n = 32), or by clinical follow-up (n = 25).
Due to loss to follow-up, five examinations (all negative
on FDG-PET/CT) could not be further validated. Verifica-
tion by biopsy was only available for one lesion per
patient; however, FDG-PET/CT was then used as the ref-
erence method for comparison of the other modalities.
The positivity of FDG-PET/CT and FDG-PET/MRI was
based on Deauville criteria and lesions with FDG uptake
higher than the liver uptake were considered positive
(Deauville scores 4 and 5) [16]. The median follow-up
estimated by the inverse Kaplan-Meier method was
9.1 months (range 0.0–21.3 months, median 8.7 months).
Statistical analysis
All statistical tests were performed using SPSS Statistics
Version 22 (IBM, Armonk, NY, USA). Quantitative
values were expressed as mean ± standard deviation or
median and range as appropriate. Comparisons of means
and related metric measurements were performed using
Student’s t-test and the Wilcoxon signed rank test, re-
spectively. All statistical tests were conducted two-sided
and a p value less than 0.05 was considered to indicate
statistical significance.
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Results
Patient characteristics
Sixty-two patients with a mean age of 55 ± 20 years (me-
dian 62; range 20–90) were prospectively included in
this study. A total of 82 examinations were performed
for primary staging (n = 14) and restaging (n = 68). Re-
staging consisted of interim examinations during ongoing
therapy (n = 14), examination after end of treatment
(n = 19), and surveillance (n = 35).
The majority of the examinations were done for assess-
ment of Hodgkin’s disease (n = 28) or diffuse large B-cell
lymphoma (n = 26) (for details, see Table 2). One patient
who presented with suspicion for lymphoma was found to
have sarcoidosis upon histologic verification and was later
excluded, leaving 61 patients for lymphoma analysis.
Detectability rate
Overall, 188 lesions were considered positive in 29
examinations in 27 patients (see Table 3). Another 53
examinations in 34 patients were considered negative
for lymphoma.
FDG-PET/MRI accurately detected 188 lesions, yield-
ing a sensitivity of 100 % compared with FDG-PET/CT.
On the other hand, WB-DW-MRI detected 524 lesions,
of which 125 (66.5 % of 188) lesions were true positive
and 319 false positive findings. WB-DW-MRI accord-
ingly missed 63 true positive (33.5 % of 188) lesions.
Detection of nodal vs. extranodal disease
Of the 188 lesions positive for lymphoma, 170 repre-
sented nodal disease while 18 were found in extranodal
sites. The distribution of FDG-positive lymphoma mani-
festations according to localization is shown in Table 4.
FDG-PET/MRI detected all 170 instances of nodal dis-
ease and also identified all 18 extranodal lymphoma
manifestations; by comparison, WB-DW-MRI character-
ized 115 (67.6 %) and 10 (55.6 %) lesions as positive for
nodal and extranodal disease, respectively (Fig. 1). Among
the extranodal manifestations, splenic involvement was
the source of the greatest discrepancy, with WB-DW-MRI
detecting only 50 % of cases and yielding false positive
findings in three other patients (Fig. 2).
Table 2 Patient characteristics
Lymphoma entity Examinations Patients
Hodgkin’s disease 28 21
DLBCL 26 18
CLL 2 2
Follicular lymphoma 5 5
MALT 1 1
Mantle cell lymphoma 11 6
Marginal cell lymphoma 2 2
Peripheral T-cell lymphoma 2 2
Peripheral B-cell lymphoma 1 1
Large cell lymphoma 1 1
Angioblastic lymphoma 2 1
Sarcoidosis (excluded) 1 1
Mycosis fungoides 1 1
Total included 82 61
Abbreviations: DLBCL diffuse large B-cell lymphoma, CLL chronic lymphocytic
leukemia, MALT mucosa-associated lymphoid tissue
Table 3 Clinical consensus in respect of Ann Arbor stage
Stage I Stage II Stage III Stage IV
All 6 8 8 7
Primary staging 3 2 6 2
Interim scan 1 1 1 1
End of Tx 1 2 0 1
Surveillance 1 3 1 3
Table 4 Lymphoma manifestations according to the German
Hodgkin Study Group (GHSG) protocol guidelines (n = 188)
Region N
Waldeyer left 3
Waldeyer right 4
Upper cervical left 9
Upper cervical right 9
Cervical left 11
Cervical right 10
Supraclavicular left 11
Supraclavicular right 10
Infraclavicular left 9
Infraclavicular right 7
Axillary left 7
Axillary right 8
Upper mediastinum 12
Lower mediastinum 10
Lung hilum left 2
Lung hilum right 5
Spleen 6
Splenic hilum 1
Liver hilum 4
Celiac 4
Para-aortic 6
Mesenteric 6
Iliac left 4
Iliac right 9
Inguinal left 3
Inguinal right 8
Organ 10
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Staging vs. restaging
Among the 188 lesions positive for lymphoma, 113
(60.1 %) were found in patients included for primary sta-
ging and 75 (39.9 %) in those included for restaging.
Among the primary staging patients, FDG-PET/MRI ac-
curately detected all positive lesions while WB-DW-MRI
identified 73 (64.6 %) lesions. Among the patients under-
going restaging, FDG-PET/MRI and WB-DW-MRI char-
acterized 75 (100 %) and 52 (69.3 %) lesions, respectively.
Interim vs. end of treatment vs. surveillance
FDG-PET/CT and FDG-PET/MRI detected the same
number of lesions in patients who underwent examin-
ation during ongoing therapy (n = 16), after the end of
treatment (n = 12), and during surveillance (n = 47),
while WB-DW-MRI detected nine (56.3 %), six (50.0 %),
and 37 (78.7 %) lesions, respectively.
Hodgkin’s disease (HD) vs. diffuse large B-cell lymphoma
(DLBCL) and low- and intermediate- vs. high-grade
lymphoma
Of the 82 examinations included, 28 were indicated for
HD and 26 for DLBCL, accounting for a total number of
66 and 61 of the detected lesions, respectively. WB-DW-
MRI accurately detected 40 lesions (60.6 %) in HD
patients and 41 DLBC patients (67.2 %). Fifty-four exam-
inations were performed for evaluation of high-grade
lymphomas, with FDG-PET/MRI detecting 127 positive
lesions and WB-DW-MRI, 81 (63.8 %). The remaining
28 examinations were performed for evaluation of low-
Fig. 1 A male patient with Hodgkin’s disease stage IIIE. PET/CT/MRI after two cycles of chemotherapy. Top: Axial PET shows very faint uptake in
the anterior mediastinal lesion; axial WB-DW-MRI (b value = 800) shows restricted diffusion (calculated ADCmean = 0.96 × 10
−3 mm2/s). Bottom:
FDG-PET/CT and FDG-PET/MRI show a residual mediastinal mass without significant FDG activity. FDG-PET/CT and FDG-PET/MRI after the end of
treatment confirmed complete response
Fig. 2 A female patient with a diffuse large B-cell lymphoma stage IVB. PET/CT/MRI for initial staging. Top: Axial WB-DW-MRI (b value = 800) and
axial ADC map show restricted diffusion in a lymph node conglomerate in the upper abdomen (calculated ADCmean = 0.72 × 10
−3 mm2/s), but no
restricted diffusion in the spleen (calculated ADCmean = 1.37 × 10
−3 mm2/s). Axial PET shows uptake in the same lymph node conglomerate but
also diffuse uptake in the spleen, which was significantly higher than liver uptake. Bottom: FDG-PET/CT and FDG-PET/MRI show FDG avidity in
both the lymph node mass and the spleen, indicating lymphoma manifestation
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and intermediate-grade lymphomas. Here, all 61 lesions
considered positive for lymphoma were accurately de-
tected by FDG-PET/MRI, while 46 (75.4 %) were de-
tected with WB-DW-MRI.
Ann Arbor stage
In 18 examinations, WB-DW-MRI and FDG-PET/MRI
agreed with respect to Ann Arbor stage (8 stage 0, 1
stage I, 0 stage II, 4 stage III, 1 stage IIIS, and 4 stage
IV). Among the other 64 examinations, WB-DW-MRI
resulted in upstaging in 60 cases, including 45 patients
who were free of disease as determined by FDG-PET/
CT (WB-DW-MRI changed the stage from 0 to I in 9
patients, 0 to II in 10 patients, 0 to III in 25 patients,
and 0 to IV in 1 patient), and downstaging in four (from
IIIS to III in 1 patient and from IV to III in 3 patients).
Among the 27 patients with positive findings for lymph-
oma, WB-DW-MRI and FDG-PET/MRI agreed in ten
patients (34.5 %) while upstaging was observed in 15
(51.7 %) and downstaging in four (13.8 %).
A summary of the comparative results for FDG-PET/
CT, FDG-PET/MRI, and WB-DW-MRI is provided in
Table 5.
Discussion
The results of this study show that the diagnostic per-
formance of FDG-PET/MRI in lymphoma patients in a
realistic everyday clinical setting is equal to that of FDG-
PET/CT, which is nowadays widely accepted as the mo-
dality of choice for staging and restaging of lymphoma
patients. On the other hand, the performance of WB-DW-
MRI seems to be inferior to that of FDG-PET/CT/MRI in
various respects, most notably for staging, differentiation
of nodal and extranodal disease, and differentiation of
high-grade and low-grade lymphoma. The perform-
ance of WB-DW-MRI was better for evaluation dur-
ing surveillance and in the assessment of low-grade
lymphomas (cf. Table 5).
FDG-PET/CT and FDG-PET/MRI showed agreement
for all lesions, which is not too surprising given that the
PET component was the same. Differences between MRI
and CT have been especially described for detection of
bone marrow (MRI superior) [17] and lung involvement
[3] (CT superior). However, in our study population, in
which lung involvement was present in only three pa-
tients and bone marrow involvement in only one patient,
FDG-PET/CT and FDG-PET/MRI were in agreement
due to the increased FDG uptake in all corresponding
lesions.
The equivalent performance of FDG-PET/CT and
FDG-PET/MRI in patients with lymphoma was recently
confirmed in a retrospective study including 33 patients
and a total of 702 lymph node stations [18]. Using FDG-
PET/CT as the reference standard, FDG-PET/MRI had a
sensitivity of 93.8 % and a specificity of 99.4 %, results
which are in line with those of our study.
For WB-DW-MRI, ADC values were determined for
any lesions visually detectable, as no definite cut-offs
have previously been reported. We evaluated the entire
data set using different cut-offs for the ADC (data not
shown), and the cut-off selected (mean ADC threshold
of 1.2 × 10–3 mm2/s) performed best in terms of overall
accuracy. Nevertheless, the difficulty in identification of
a cut-off explains the very high number of false positive
lesions on WB-DW-MRI, which in general detected
two-thirds of lymphoma lesions. Difficulty in deriving an
optimal cut-off for the ADC value was also reported by
Punwani et al. in 39 patients undergoing WB-DW-MRI
and FDG-PET/CT before and after two cycles of chemo-
therapy. Interim ADC values in patients with adequate
FDG-PET/CT response were not statistically different
from those in patients without an adequate response [7].
PET imaging detects lymphoma activity on the basis of
tumor glucose metabolism, while WB-DW-MRI does so
on the basis of the motion of water molecules in a
densely cellular environment. Our findings show – as do
those of several previous publications – that tumor cel-
lularity as detected by WB-DW-MRI may not be an
adequate marker for lymphoma activity to the same
extent as glycolytic metabolism. This inference is sup-
ported by the findings of Wu et al., who concluded, on
the basis of results in patients with histologically proven
DLBCL, that SUV for PET and ADC for WB-DW-MRI
are different indices for the characterization of lymph-
omas [19].
When our patient population was categorized into dif-
ferent subsets according to lymphoma manifestation
(nodal vs. extranodal disease), indication (staging vs.
Table 5 Comparison of number of positive lymphoma lesions
detected by FDG-PET/CT, FDG-PET/MRI, and WB-DW-MRI
PET/CT = PET/
MRI
WB-DW-
MRI
Detectability rate
with WB-DW-MRI
P value
Lesions detected 188 125 66.5 % <0.001
Nodal disease 170 115 67.6 % <0.001
Extranodal disease 18 10 55.6 % 0.004
Staging 113 73 64.6 % 0.008
Restaging 75 52 69.3 % 0.010
Interim 16 9 56.3 % 0.169
End of treatment 12 6 50.0 % 0.083
Surveillance 47 37 78.7 % 0.058
High-grade 127 81 63.8 % 0.003
Low-grade 61 46 75.4 % 0.032
HD 66 40 60.6 % 0.006
DLBCL 61 41 67.2 % 0.009
Abbreviations: HD Hodgkin’s disease, DLBCL diffuse large B-cell lymphoma
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restaging), timepoint of examination (during ongoing
therapy, after end of treatment, and surveillance) and
grade of lymphoma (low- vs. high-grade and HD vs.
DLBCL), WB-DW-MRI failed to achieve the lesion de-
tectability offered by FDG-PET/CT or FDG-PET/MRI in
any of the subsets. Kwee et al. recently reported that
WB-DW-MRI did not provide any advantage over MRI
without DWI in 108 newly diagnosed lymphoma pa-
tients [3]. Slightly improved results were reported by
Tsuji et al., who compared FDG-PET/CT and MRI in 28
malignant lymphoma patients prior to any treatment
and after two cycles of chemotherapy [20]. While con-
cordant findings were reported in 22/28 (79 %) patients,
significant differences were nevertheless found between
FDG-PET/CT and MRI. The best results were obtained
in the study of Mayerhoefer and co-workers, who re-
ported WB-DW-MRI to have a region-based sensitivity
of 97 % compared with FDG-PET/CT in known FDG-
avid lymphoma histologic subtypes [21].
In our study, the results of WB-DW-MRI were not sta-
tistically different from those of the reference standard,
FDG-PET/CT, with respect to interim/end of treatment
imaging and surveillance. These findings are to an extent
similar to the results of Mayerhoefer and co-workers in
lymphomas with variable FDG avidity [21]. However, the
impact of the low numbers of lesions in the relevant sub-
sets in our study has to be borne in mind.
As WB-DW-MRI achieved an almost comparable
detection rate to FDG-PET/CT among patients undergo-
ing surveillance, this method might be considered for
follow-up of this subgroup of patients when baseline im-
aging with WB-DW-MRI is available, especially given
that FDG-PET/CT in general is not recommended for
this purpose [1].
WB-DW-MRI showed inferior results in the evalu-
ation of extranodal disease and for overall restaging.
Only a few studies have evaluated the accuracy of WB-
DW-MRI and FDG-PET/MRI for detection of extrano-
dal disease. Results of other studies have suggested that,
overall, WB-DW-MRI and FDG-PET/MRI may have an
advantage compared with FDG-PET/CT for this purpose
[22, 23], especially when considering bone marrow in-
volvement. In our study, only one patient presented
bone marrow infiltration, so we cannot offer further
comment on this aspect. However, we did find that dif-
fuse splenic involvement may not be reliably detected by
WB-DW-MRI; this confirms previous observations by
Toledano-Massiah and colleagues [22] and reflects the
fact that restricted diffusion may be observed even in a
normal spleen.
For therapy response assessment, FDG-PET/MRI has
proved to be feasible and reliable [24]. Most studies de-
scribe an elevation in the ADC mean value as suggestive
of response to treatment [25–27]. Our study has shown
that, when used for restaging, WB-DW-MRI performed
less well than FDG-PET/MRI in detecting lymphoma
activity. This finding suggests that the use of WB-DW-
MRI to assess treatment response of lymphoma may
underestimate the true number of lesions and that care-
ful evaluation is required in order to avoid false negative
findings.
We observed only moderate agreement between WB-
DW-MRI and FDG-PET/MRI or FDG-PET/CT concern-
ing determination of the Ann Arbor stage. One of the
reasons for this may be the lack of standardized criteria
for definition of lymphoma involvement on WB-DW-
MRI, which may be considered responsible for the very
high number of false positive lesions in our study. As
indicated above, we tested our results with different
ADC thresholds (data not shown). When the threshold
was changed, however, the values for sensitivity and spe-
cificity altered in opposite directions (e.g., sensitivity
increased but specificity decreased) and no improvement
in overall accuracy was achieved. Another drawback is
that no parameters have been defined for the evaluation
of extranodal disease. Hence, the reproducibility of WB-
DW-MRI is limited and may also be partly dependent
on the MRI scanner used.
Overall, our results indicate that the similarity in diag-
nostic performance of FDG-PET/CT and FDG-PET/MRI
reported previously in various solid tumors also holds
true for FDG-avid lymphoma types. While the findings
of most studies cited above are generally in line with our
own results, the reported inferiority of WB-DW-MRI
compared with FDG-PET-based techniques is somewhat
at odds with a few other studies in the literature. One
potential explanation is our choice of everyday setting
including a wide range of histologies and different clin-
ical situations ranging from staging to surveillance, as
well as the use of a tri-modality system with MRI being
performed separately from the PET component. More-
over, it is well known that bone marrow, spleen, and
lymph nodes retain high signal intensity and are there-
fore difficult to assess with WB-DW-MRI [28].
When interpreting the results of this study, several
limitations have to be taken into account. First, histo-
pathology as the reference standard of choice was not
available in all lesions (ethically this was not possible),
though it was usually available in patients referred for ini-
tial staging. However, FDG-PET/CT is widely accepted as
a reference standard to determine disease in lymphoma
[1]. Additionally, our study did not define a threshold for
lesion size in WB-DW-MRI and consequently, we de-
tected a very high number of false positive lesions, result-
ing in overestimated upstaging. However, even without
such a threshold, WB-DW-MRI was unable to detect all
of the lesions that were positive on FDG-PET. Finally, we
used a tri-modality PET/CT-MRI setup rather than
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simultaneous PET//MRI and thus the attenuation correc-
tion for the PET component was always based on the low-
dose CT.
Conclusion
In summary, our results indicate that FDG-PET/CT and
FDG-PET/MRI have a similar performance in the clinical
work-up of lymphomas, while WB-DW-MRI is inferior to
both FDG-PET-based methods. WB-DW-MRI can, how-
ever, be used in specific scenarios, e.g., in low-grade
lymphomas as well as imaging during surveillance.
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